IFRX - InflaRx N.V.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

InflaRx N.V.

Winzerlaer Str. 2
Jena 07745
Germany
49 3641 508 180
http://www.inflarx.de

Sector : Healthcare
Industry : Biotechnology
Full Time Employees : 36

Key Executives

Name Title Pay Exercised Year Born
Dr. Niels C. Riedemann M.D., Ph.D. Co-Founder, CEO & Exec. Director N/A N/A 1972
Prof. Renfeng Guo Co-Founder, Chief Scientific Officer & Exec. Director N/A N/A 1970
Mr. Arnd Christ Chief Financial Officer N/A N/A 1966
Mr. Jason M. Marks J.D. Chief Legal Officer, Gen. Counsel & Corp. Sec. N/A N/A 1976
Mr. Jordan Silverstein Head of Corp. Devel. & Strategy N/A N/A N/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in the United States and Europe. Its C5a is an inflammatory mediator is involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, an intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase II clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of pyoderma gangrenosum, a chronic inflammatory skin disorder, as well as developing IFX-1 for the treatment of oncological diseases. It also develops IFX-2 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. The company has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

Corporate Governance

InflaRx N.V.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS) . Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.